A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Inclusion Criteria: * Male and female patients aged over 18 years * Histologically proven lung adenocarcinoma * clinical stage IIIB/IV * ECOG performance status 0-2 * Had no prior anticancer agent, radiation or surgical therapy for lung adenocarcinoma * At least one measurable lesion (according to RECIST) * Provision of written informed consent * Life expectancy of at least 12 weeks Exclusion Criteria: * History of malignant disease. * Evidence of clinically active interstitial lung diseases (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded) * Expected life expectancy less than 2 months * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) * Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 2.5 x ULN if no demonstrable liver metastases (or \>5 x in presence of liver metastases) * Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study * Pregnancy or breast-feeding women (women of child¬bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.